| Company/Division name | Otsuka ICU Medical |
| Parent company | Otsuka Pharmaceutical Factory America |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Offshore, work was done: | In-house |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 500 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Austin |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | IV Solutions |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Better Control of Process/Delivery/Factory, Government Incentives, Lead time/Time to market, Proximity to customers/market |
